- Home
- MEGI vs IMTX Comparison
MEGI vs IMTX Comparison
Compare MEGI & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MEGI
- IMTX
- Stock Information
- Founded
- MEGI 2021
- IMTX N/A
- Country
- MEGI United States
- IMTX Germany
- Employees
- MEGI N/A
- IMTX N/A
- Industry
- MEGI Investment Managers
- IMTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MEGI Finance
- IMTX Health Care
- Exchange
- MEGI Nasdaq
- IMTX Nasdaq
- Market Cap
- MEGI 749.0M
- IMTX 653.9M
- IPO Year
- MEGI N/A
- IMTX N/A
- Fundamental
- Price
- MEGI $14.43
- IMTX $5.69
- Analyst Decision
- MEGI
- IMTX Strong Buy
- Analyst Count
- MEGI 0
- IMTX 4
- Target Price
- MEGI N/A
- IMTX $14.67
- AVG Volume (30 Days)
- MEGI 178.0K
- IMTX 572.9K
- Earning Date
- MEGI 01-01-0001
- IMTX 08-13-2025
- Dividend Yield
- MEGI 11.40%
- IMTX N/A
- EPS Growth
- MEGI N/A
- IMTX N/A
- EPS
- MEGI N/A
- IMTX N/A
- Revenue
- MEGI N/A
- IMTX $152,823,253.00
- Revenue This Year
- MEGI N/A
- IMTX N/A
- Revenue Next Year
- MEGI N/A
- IMTX $1.92
- P/E Ratio
- MEGI N/A
- IMTX N/A
- Revenue Growth
- MEGI N/A
- IMTX 83.61
- 52 Week Low
- MEGI $10.63
- IMTX $3.30
- 52 Week High
- MEGI $14.89
- IMTX $13.09
- Technical
- Relative Strength Index (RSI)
- MEGI 54.89
- IMTX 41.21
- Support Level
- MEGI $14.26
- IMTX $5.42
- Resistance Level
- MEGI $14.50
- IMTX $6.47
- Average True Range (ATR)
- MEGI 0.13
- IMTX 0.36
- MACD
- MEGI -0.01
- IMTX -0.11
- Stochastic Oscillator
- MEGI 62.12
- IMTX 21.77
About MEGI MainStay CBRE Global Infrastructure Megatrends Term Fund
NYLI CBRE Global Infrastructure Megatrends Term Fund is a non-diversified, closed-end management investment company. The Fund's investment objective is to seek a high level of total return with an emphasis on current income. It is focused on the investment megatrends of decarbonization, digital transformation and asset modernization, which are reshaping the demand for infrastructure assets and driving income and growth potential.
About IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.